Part A: Screening and Study Follow-Up
Part A lasts up to 24 weeks from the first dose and is for all participants who meet certain criteria to take part in the study.
Study treatment is either the investigational therapy CP101 or placebo. Your chance of receiving CP101 is two times higher than that of receiving placebo.
Part B: Optional
Part B is optional. Not everyone will be able to enter Part B of the study. You may be able to take part in Part B of the study if you develop diarrhea which tests positive for C. diff in the first 8 weeks after taking study drug in Part A.
Everyone in Part B receives the investigational therapy CP101 (there is no chance of receiving placebo in Part B).